Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891150573> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2891150573 abstract "e15598 Background: Esophageal adenocarcinoma (EAC) is a leading cause of cancer death, and current treatment options are extremely limited. Cell cycle regulators CDK6 and its homolog, CDK4, are known to be up-regulated in EAC and are associated with poor prognosis. At the molecular level, CDK4 and 6 bind to cyclin D1 and activates E2F transcription factor via phosphorylation of pRb. Up-regulation of this pathway leads to deregulation of the G1 checkpoint, resulting in increased cellular proliferation. Previously, studies have shown progressive up-regulation of CDK6 in pre-neoplastic lesions from Barrett’s esophagus to low-grade and high-grade dysplasia, thus establishing a rational for testing of a CDK4/6 dual inhibitor, Abemaciclib, in an established EAC model. Methods: Esophagojejunostomy was performed on Sprague-Dawley rats to induce gastroduodenojejunal reflux resulting in a sequence of histologic and molecular events that lead to the development esophageal adenocarcinoma. At 36 weeks post operatively, rats were randomized to receive Abemaciclib at 26 mg/kg or placebo (acetate buffer), intraperitoneally once daily for 4 weeks. Drug efficacy was evaluated with magnetic resonance imaging (MRI), endoscopic biopsy, histology, and CDK4/6 pathway expression by RT-PCR. Results: Twelve of 15 (80.0%) treated animals and all of 18 (100%) control animals reached study end-point. All of the treatment group mortality consisted of rats afflicted with moderate peritonitis, diarrhea and weight loss. Mean MRI tumor volume decreased by 93.55% in treatment animals and increased by 108.33% in control animals (P = 0.003). Treatment with Abemaciclib demonstrated tumor volume increase in 0% (control = 66.7%) (P = 0.0003), decrease in 75% (control = 0%) (P = 0.00001), and stable volume in 25% (control = 33.3%) (P = 0.63). EAC prevalence in treatment animals decreased by 50%; whereas, prevalence in control animals increased by 5.6% (P = 0.003). mRNA expression, pre- and post-treatment, demonstrated significant downregulation of CDK4, CDK6, RB1, pRB1 and Cyclin-D. Conclusions: Abemaciclib exhibits potent in vivo antitumor efficacy in a de novo EAC model, providing the rationale for clinical testing." @default.
- W2891150573 created "2018-09-27" @default.
- W2891150573 creator A5009652529 @default.
- W2891150573 creator A5014036462 @default.
- W2891150573 creator A5031889639 @default.
- W2891150573 creator A5036615948 @default.
- W2891150573 creator A5050036111 @default.
- W2891150573 creator A5059886787 @default.
- W2891150573 creator A5069047119 @default.
- W2891150573 date "2017-05-20" @default.
- W2891150573 modified "2023-09-25" @default.
- W2891150573 title "Antitumor efficacy of CDK 4/6 dual inhibitor, abemaciclib, in an esophageal adenocarcinoma model." @default.
- W2891150573 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e15598" @default.
- W2891150573 hasPublicationYear "2017" @default.
- W2891150573 type Work @default.
- W2891150573 sameAs 2891150573 @default.
- W2891150573 citedByCount "1" @default.
- W2891150573 countsByYear W28911505732021 @default.
- W2891150573 crossrefType "journal-article" @default.
- W2891150573 hasAuthorship W2891150573A5009652529 @default.
- W2891150573 hasAuthorship W2891150573A5014036462 @default.
- W2891150573 hasAuthorship W2891150573A5031889639 @default.
- W2891150573 hasAuthorship W2891150573A5036615948 @default.
- W2891150573 hasAuthorship W2891150573A5050036111 @default.
- W2891150573 hasAuthorship W2891150573A5059886787 @default.
- W2891150573 hasAuthorship W2891150573A5069047119 @default.
- W2891150573 hasConcept C121608353 @default.
- W2891150573 hasConcept C124320809 @default.
- W2891150573 hasConcept C126322002 @default.
- W2891150573 hasConcept C143998085 @default.
- W2891150573 hasConcept C2778298596 @default.
- W2891150573 hasConcept C2779742542 @default.
- W2891150573 hasConcept C2781025758 @default.
- W2891150573 hasConcept C2781182431 @default.
- W2891150573 hasConcept C29537977 @default.
- W2891150573 hasConcept C2992824209 @default.
- W2891150573 hasConcept C502942594 @default.
- W2891150573 hasConcept C71924100 @default.
- W2891150573 hasConcept C98274493 @default.
- W2891150573 hasConceptScore W2891150573C121608353 @default.
- W2891150573 hasConceptScore W2891150573C124320809 @default.
- W2891150573 hasConceptScore W2891150573C126322002 @default.
- W2891150573 hasConceptScore W2891150573C143998085 @default.
- W2891150573 hasConceptScore W2891150573C2778298596 @default.
- W2891150573 hasConceptScore W2891150573C2779742542 @default.
- W2891150573 hasConceptScore W2891150573C2781025758 @default.
- W2891150573 hasConceptScore W2891150573C2781182431 @default.
- W2891150573 hasConceptScore W2891150573C29537977 @default.
- W2891150573 hasConceptScore W2891150573C2992824209 @default.
- W2891150573 hasConceptScore W2891150573C502942594 @default.
- W2891150573 hasConceptScore W2891150573C71924100 @default.
- W2891150573 hasConceptScore W2891150573C98274493 @default.
- W2891150573 hasLocation W28911505731 @default.
- W2891150573 hasOpenAccess W2891150573 @default.
- W2891150573 hasPrimaryLocation W28911505731 @default.
- W2891150573 hasRelatedWork W2589815784 @default.
- W2891150573 hasRelatedWork W2601079093 @default.
- W2891150573 hasRelatedWork W2764322797 @default.
- W2891150573 hasRelatedWork W2778889768 @default.
- W2891150573 hasRelatedWork W2779538465 @default.
- W2891150573 hasRelatedWork W2921951334 @default.
- W2891150573 hasRelatedWork W2971050114 @default.
- W2891150573 hasRelatedWork W2995918299 @default.
- W2891150573 hasRelatedWork W3006035456 @default.
- W2891150573 hasRelatedWork W3007479170 @default.
- W2891150573 hasRelatedWork W3026768987 @default.
- W2891150573 hasRelatedWork W3027984788 @default.
- W2891150573 hasRelatedWork W3100009242 @default.
- W2891150573 hasRelatedWork W3106785508 @default.
- W2891150573 hasRelatedWork W3150383426 @default.
- W2891150573 hasRelatedWork W3180881022 @default.
- W2891150573 hasRelatedWork W3196648022 @default.
- W2891150573 hasRelatedWork W3199373900 @default.
- W2891150573 hasRelatedWork W3207757747 @default.
- W2891150573 hasRelatedWork W1565833750 @default.
- W2891150573 isParatext "false" @default.
- W2891150573 isRetracted "false" @default.
- W2891150573 magId "2891150573" @default.
- W2891150573 workType "article" @default.